Rigel Pharmaceuticals INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Rigel Pharmaceuticals' 10-K filing reveals a year of increased product sales and strategic pipeline advancements, including the acquisition of GAVRETO and progress in IRAK 1/4 inhibitor development.
NASDAQ
10-K: Rigel Pharmaceuticals Reports Full Year 2023 Results, Expands Portfolio with Gavreto Acquisition
Rigel Pharmaceuticals reports a 24% increase in TAVALISSE sales and a significant jump in REZLIDHIA sales, while also acquiring rights to GAVRETO in the US.